OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
How to handle side effects of enfortumab vedotin + pembrolizumab

How to handle side effects of enfortumab vedotin + pembrolizumab

by Alison Birtle | 5 June 2024 | Urogenital

Enfortumab vedotin (EV) plus pembrolizumab has recently been established as the new first-line treatment standard in advanced urothelial carcinoma. Clear guidance on how to manage the typical side effects of this regimen is necessary to allow for the successful use of...
EMA approves nivolumab + cisplatin and gemcitabine for 1L treatment of mUC

EMA approves nivolumab + cisplatin and gemcitabine for 1L treatment of mUC

by EMA Approval | 29 May 2024 | Urogenital

The European Commission has approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic Urothelial Carcinoma. Nivolumab in combination with cisplatin and gemcitabine has now become the first...
Next Entries »

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}